Literature DB >> 26687641

Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.

Janouk Diphoorn1,2,3, Simone Cazzaniga2,4, Chiara Gamba1, Jan Schroeder5, Antonella Citterio6, Alma Lisa Rivolta7, Giuseppe Danilo Vighi8, Luigi Naldi1,2.   

Abstract

PURPOSE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutaneous adverse drug reactions. We assessed incidence, drug exposure and mortality, analysing data obtained from the Lombardy Registry of Severe Cutaneous Reactions (REACT).
METHODS: Data were collected from hospitals in the Italian Lombardy region (9,502,272 people). A trained monitor was sent to the reporting hospital to collect data on drug exposure and clinical features. The algorithm for drug causality for epidermal necrolysis algorithm was applied to assess drug causality. Defined Daily Dose (DDD) was used to express drug consumption.
RESULTS: From April 2009 to November 2014, 17 cases of TEN and 59 cases of SJS were collected. The overall incidence rate was 1.40 cases (95%CI, 1.12-1.76) per million people per year. A total of 15 cases died during hospitalization with a mortality rate of 16.9% for SJS and 29.4% for TEN. Overall, 55.4% of cases had a probable or very probable relation with drug exposure. In a total of five patients (6.6%), no causative drug for the reaction was identifiable. Allopurinol contributed to the highest number of cases (23 cases), while the highest incidence based on more than one case reported was observed for cotrimoxazole and lamotrigine, with 5.37 cases (95%CI, 2.09-13.80) and 3.54 (95%CI, 1.21-10.42) per 10 million DDD/year, respectively.
CONCLUSIONS: We confirmed that SJS and TEN are rare adverse cutaneous reactions. As expected, mortality was influenced by the degree of skin detachment. The profile of drugs associated with the reactions was in agreement with data from other surveillance systems.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Stevens-Johnson syndrome (SJS); causal factors/aetiology; incidence; mortality; pharmacoepidemiology; pharmacovigilance; toxic epidermal necrolysis (TEN)

Mesh:

Substances:

Year:  2015        PMID: 26687641     DOI: 10.1002/pds.3937

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  13 in total

Review 1.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Authors:  Gianluca Trifirò; Rosa Gini; Francesco Barone-Adesi; Ettore Beghi; Anna Cantarutti; Annalisa Capuano; Carla Carnovale; Antonio Clavenna; Mirosa Dellagiovanna; Carmen Ferrajolo; Matteo Franchi; Ylenia Ingrasciotta; Ursula Kirchmayer; Francesco Lapi; Roberto Leone; Olivia Leoni; Ersilia Lucenteforte; Ugo Moretti; Alessandro Mugelli; Luigi Naldi; Elisabetta Poluzzi; Concita Rafaniello; Federico Rea; Janet Sultana; Mauro Tettamanti; Giuseppe Traversa; Alfredo Vannacci; Lorenzo Mantovani; Giovanni Corrao
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

2.  A cross-sectional comparative study on chronic ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series.

Authors:  Loraine L W Chow; Alex L K Ng; Sharon S W Chow; Bonnie N K Choy; Kendrick C Shih; Ian Y H Wong; Johnny C Y Chan; Jimmy S M Lai
Journal:  Int Ophthalmol       Date:  2017-05-25       Impact factor: 2.031

3.  A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?

Authors:  Carlo Maria Rossi; Flavio Niccolò Beretta; Grazia Traverso; Sandro Mancarella; Davide Zenoni
Journal:  Clin Mol Allergy       Date:  2020-10-06

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 5.  An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.

Authors:  Chun-Bing Chen; Riichiro Abe; Ren-You Pan; Chuang-Wei Wang; Shuen-Iu Hung; Yi-Giien Tsai; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2018-02-13       Impact factor: 4.818

6.  Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital.

Authors:  Susheera Chatproedprai; Vanvara Wutticharoenwong; Therdpong Tempark; Siriwan Wananukul
Journal:  Dermatol Res Pract       Date:  2018-05-07

7.  Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.

Authors:  Cristina Scavone; Cristina Di Mauro; Rosanna Ruggiero; Francesca Futura Bernardi; Ugo Trama; Maria Luisa Aiezza; Concetta Rafaniello; Annalisa Capuano
Journal:  Drugs Real World Outcomes       Date:  2020-03

8.  Factors Predicting the Outcome of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 5-Year Retrospective Study.

Authors:  Vishal Thakur; Keshavamurthy Vinay; Sheetanshu Kumar; Rajat Choudhary; Ashok Kumar; Davinder Parsad; Muthu Sendhil Kumaran
Journal:  Indian Dermatol Online J       Date:  2021-03-02

9.  Understanding Immune Responses to Surgical Transplant Procedures in Stevens Johnsons Syndrome Patients.

Authors:  Matias Soifer; Hazem M Mousa; Robert B Levy; Victor L Perez
Journal:  Front Med (Lausanne)       Date:  2021-05-21

10.  Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database.

Authors:  Bernardo Sousa-Pinto; Luís Araújo; Alberto Freitas; Osvaldo Correia; Luís Delgado
Journal:  Clin Transl Allergy       Date:  2018-01-22       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.